TLSI
TriSalus Life Sciences, Inc.
-0.04 (-0.81%)4.89USD30.3K成交股數301M市值–本益比(近四季)6.7股價營收比+1.7%營收年增(近四季)2026-11-12下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 1.8M · 1K |
| 近 180 天 淨額 | 1.8M |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | 07-06 | Patience David | Chief Financial Officer | F 繳稅扣股 | 14.7K | 4.46 | 65K | 261K | SEC |
| 2026-06-30 | 07-01 | Marshak Richard | Chief Commercial Officer | A 獲配股票 | 561 | 3.87 | 2K | 128K | SEC |
| 2026-06-30 | 07-01 | Szela Mary T | CEO and President | A 獲配股票 | 4.0K | 3.87 | 15K | 1.1M | SEC |
| 2026-06-29 | 06-29 | Marshall Richard Henry | Chief Medical Officer | A 獲配股票 | 60.0K | – | – | 90.0K | SEC |
| 2026-05-15 | 05-19 | Marshak Richard | Chief Commercial Officer | S 公開市場賣出 | 543 | 2.67 | 1K | 125K | SEC |
| 2026-05-15 | 05-18 | Stansky Michael P | Director | P 公開市場買進 | 200K | 2.50 | 500K | 400K | SEC |
| 2026-05-15 | 05-18 | Stansky Michael P | Director | P 公開市場買進 | 410K | 2.50 | 1.0M | 1.2M | SEC |
| 2026-05-15 | 05-18 | Szela Mary T | CEO and President | P 公開市場買進 | 39.7K | 2.59 | 103K | 1.1M | SEC |
| 2026-05-15 | 05-18 | Wahlstrom Mats | Director | P 公開市場買進 | 60.0K | 2.53 | 152K | 148K | SEC |
| 2026-05-15 | 05-18 | Patience David | Chief Financial Officer | P 公開市場買進 | 7.1K | 2.43 | 17K | 276K | SEC |
| 2026-05-15 | 05-18 | Gordon Gary B. | Director | P 公開市場買進 | 10.0K | 2.46 | 25K | 72.5K | SEC |
| 2026-05-14 | 05-15 | MATLIN DAVID J | Director | A 獲配股票 | 28.2K | – | – | 1.3M | SEC |
| 2026-05-14 | 05-15 | Gordon Gary B. | Director | A 獲配股票 | 28.2K | – | – | 38.0K | SEC |
| 2026-05-14 | 05-15 | Gordon Gary B. | Director | A 獲配股票 | 24.6K | – | – | 62.5K | SEC |
| 2026-05-14 | 05-15 | Wahlstrom Mats | Director | A 獲配股票 | 37.6K | – | – | 53.3K | SEC |
| 2026-05-14 | 05-15 | HICKS KERRY R | Director | A 獲配股票 | 28.2K | – | – | 543K | SEC |
| 2026-05-14 | 05-15 | Wahlstrom Mats | Director | A 獲配股票 | 34.2K | – | – | 87.6K | SEC |
| 2026-05-14 | 05-15 | MATLIN DAVID J | Director | A 獲配股票 | 23.1K | – | – | 1.3M | SEC |
| 2026-05-14 | 05-15 | Stansky Michael P | Director | A 獲配股票 | 23.5K | – | – | 811K | SEC |
| 2026-05-14 | 05-15 | Stansky Michael P | Director | A 獲配股票 | 20.1K | – | – | 831K | SEC |
| 2026-05-14 | 05-15 | Valle William | Director | A 獲配股票 | 28.2K | – | – | 58.7K | SEC |
| 2026-05-14 | 05-15 | Valle William | Director | A 獲配股票 | 24.6K | – | – | 83.2K | SEC |
| 2026-03-17 | 03-20 | Szela Mary T | CEO and President | S 公開市場賣出 | 15.9K | 3.85 | 61K | 753K | SEC |
| 2026-03-16 | 03-20 | Devlin Jodi | Chief of Clinical Operations | S 公開市場賣出 | 273 | 4.12 | 1K | 97.4K | SEC |
| 2026-03-16 | 03-20 | Cox Bryan F. | Chief of Research | S 公開市場賣出 | 579 | 4.12 | 2K | 163K | SEC |
| 2026-03-16 | 03-20 | Marshak Richard | Chief Commercial Officer | S 公開市場賣出 | 419 | 4.12 | 2K | 110K | SEC |
| 2026-03-16 | 03-20 | Stevens Jennifer | Chief Regulatory Officer | S 公開市場賣出 | 774 | 4.12 | 3K | 124K | SEC |
| 2026-03-12 | 03-20 | Marshak Richard | Chief Commercial Officer | S 公開市場賣出 | 1.6K | 4.09 | 6K | 111K | SEC |
| 2026-03-12 | 03-20 | Cox Bryan F. | Chief of Research | S 公開市場賣出 | 1.5K | 4.09 | 6K | 164K | SEC |
| 2026-03-12 | 03-20 | Stevens Jennifer | Chief Regulatory Officer | S 公開市場賣出 | 1.6K | 4.09 | 6K | 125K | SEC |
| 2026-03-12 | 03-20 | Devlin Jodi | Chief of Clinical Operations | S 公開市場賣出 | 1.8K | 4.09 | 7K | 97.6K | SEC |
| 2026-03-11 | 03-20 | Marshak Richard | Chief Commercial Officer | S 公開市場賣出 | 1.4K | 4.13 | 6K | 112K | SEC |
| 2026-03-11 | 03-20 | Szela Mary T | CEO and President | S 公開市場賣出 | 4.4K | 4.13 | 18K | 769K | SEC |
| 2026-03-11 | 03-20 | Stevens Jennifer | Chief Regulatory Officer | S 公開市場賣出 | 1.2K | 4.13 | 5K | 126K | SEC |
| 2026-03-11 | 03-20 | Devlin Jodi | Chief of Clinical Operations | S 公開市場賣出 | 1.2K | 4.13 | 5K | 99.4K | SEC |
| 2026-03-11 | 03-20 | Cox Bryan F. | Chief of Research | S 公開市場賣出 | 1.1K | 4.13 | 5K | 165K | SEC |
| 2026-02-23 | 02-23 | Gordon Gary B. | Director | P 公開市場買進 | 9.8K | 4.10 | 40K | 9.8K | SEC |
| 2026-02-23 | 02-23 | Szela Mary T | CEO and President | P 公開市場買進 | 30.5K | 4.10 | 125K | 773K | SEC |
| 2026-02-23 | 02-23 | Valle William | Director | P 公開市場買進 | 30.5K | 4.10 | 125K | 30.5K | SEC |
| 2026-02-23 | 02-23 | Patience David | Chief Financial Officer | P 公開市場買進 | 3.7K | 4.10 | 15K | 269K | SEC |
| 2026-02-23 | 02-23 | Stansky Michael P | Director | P 公開市場買進 | 244K | 4.10 | 1,000K | 787K | SEC |
| 2026-02-23 | 02-23 | Stansky Michael P | Director | P 公開市場買進 | 117K | 4.10 | 481K | 200K | SEC |
| 2025-12-31 | 07-01 | Szela Mary T | CEO and President | A 獲配股票 | 2.1K | 4.38 | 9K | 1.0M | SEC |
| 2025-12-31 | 07-01 | Marshak Richard | Chief Commercial Officer | A 獲配股票 | 449 | 4.38 | 2K | 132K | SEC |
| 2025-11-24 | 11-25 | Szela Mary T | CEO and President | A 獲配股票 | 125K | – | – | 443K | SEC |
| 2025-11-24 | 11-25 | Patience David | Chief Financial Officer | A 獲配股票 | 65.0K | – | – | 265K | SEC |
| 2025-11-24 | 11-25 | Szela Mary T | CEO and President | A 獲配股票 | 300K | – | – | 743K | SEC |
| 2025-11-24 | 11-25 | Devlin Jodi | Chief of Clinical Operations | A 獲配股票 | 50.0K | – | – | 101K | SEC |
| 2025-11-24 | 11-25 | Marshak Richard | Chief Commercial Officer | A 獲配股票 | 60.0K | – | – | 114K | SEC |
| 2025-11-24 | 11-25 | Stevens Jennifer | Chief Regulatory Officer | A 獲配股票 | 50.0K | – | – | 128K | SEC |
| 2025-11-24 | 11-25 | Cox Bryan F. | Chief of Research | A 獲配股票 | 40.0K | – | – | 167K | SEC |
| 2025-08-14 | 08-15 | Patience David | Chief Financial Officer | A 獲配股票 | 200K | – | – | 200K | SEC |
| 2025-07-31 | 04-20 | Frankenius Equity AB | TenPercentOwner | C 轉換 | 759K | – | – | 7.0M | SEC |
| 2025-07-31 | 04-01 | MATLIN DAVID J | Director | C 轉換 | 330K | – | – | 1.3M | SEC |
| 2025-06-30 | 07-01 | Szela Mary T | CEO and President | A 獲配股票 | 2.8K | 4.23 | 12K | 597K | SEC |
| 2025-06-30 | 07-01 | Marshak Richard | Chief Commercial Officer | A 獲配股票 | 930 | 4.23 | 4K | 71.3K | SEC |
| 2025-05-19 | 05-21 | Cox Bryan F. | Chief of Research | S 公開市場賣出 | 4.8K | 5.18 | 25K | 119K | SEC |
| 2025-05-19 | 05-21 | Young James Emmett | Chief Financial Officer | A 獲配股票 | 13.2K | 5.18 | 68K | 49.7K | SEC |
| 2025-05-19 | 05-21 | Stevens Jennifer | Chief Regulatory Officer | A 獲配股票 | 28.5K | 5.18 | 147K | 86.3K | SEC |
| 2025-05-19 | 05-21 | Stevens Jennifer | Chief Regulatory Officer | S 公開市場賣出 | 8.7K | 5.18 | 45K | 77.6K | SEC |
| 2025-05-19 | 05-21 | Murphy Sean | Director | A 獲配股票 | 44.9K | 5.18 | 232K | 124K | SEC |
| 2025-05-19 | 05-21 | Marshak Richard | Chief Commercial Officer | A 獲配股票 | 21.4K | 5.18 | 111K | 75.7K | SEC |
| 2025-05-19 | 05-21 | Marshak Richard | Chief Commercial Officer | S 公開市場賣出 | 6.6K | 5.18 | 34K | 69.1K | SEC |
| 2025-05-19 | 05-21 | Devlin Jodi | Chief of Clinical Operations | S 公開市場賣出 | 4.8K | 5.18 | 25K | 52.8K | SEC |
| 2025-05-19 | 05-21 | Devlin Jodi | Chief of Clinical Operations | A 獲配股票 | 24.1K | 5.18 | 125K | 57.5K | SEC |
| 2025-05-19 | 05-21 | Cox Bryan F. | Chief of Research | A 獲配股票 | 15.7K | 5.18 | 81K | 124K | SEC |
| 2025-02-18 | 02-19 | Cox Bryan F. | CHIEF OF RESEARCH | A 獲配股票 | 11.4K | – | – | 108K | SEC |
| 2025-02-18 | 02-19 | Murphy Sean | Chief Manuf, Strategy&Bus Dev. | A 獲配股票 | 15.8K | – | – | 79.1K | SEC |
| 2025-02-18 | 02-19 | Stevens Jennifer | CHIEF REGULATORY OFFICER | A 獲配股票 | 14.5K | – | – | 57.9K | SEC |
| 2025-02-18 | 02-19 | Young James Emmett | Chief Financial Officer | A 獲配股票 | 14.8K | – | – | 36.5K | SEC |
| 2025-02-18 | 02-19 | Devlin Jodi | Chief of Clinical Operations | A 獲配股票 | 5.3K | – | – | 33.4K | SEC |
| 2025-02-18 | 02-19 | Szela Mary T | CEO AND PRESIDENT | A 獲配股票 | 21.1K | – | – | 465K | SEC |
| 2025-02-18 | 02-19 | Marshak Richard | Chief Commercial Officer | A 獲配股票 | 7.6K | – | – | 54.3K | SEC |
| 2025-02-05 | 02-06 | Young James Emmett | Chief Financial Officer | P 公開市場買進 | 6.0K | 5.65 | 34K | 30.0K | SEC |
| 2025-01-30 | 01-31 | Szela Mary T | CEO AND PRESIDENT | P 公開市場買進 | 5.0K | 5.28 | 26K | 444K | SEC |
| 2025-01-29 | 01-31 | Szela Mary T | CEO AND PRESIDENT | P 公開市場買進 | 5.0K | 5.03 | 25K | 439K | SEC |
| 2025-01-28 | 01-29 | Szela Mary T | CEO AND PRESIDENT | P 公開市場買進 | 4.7K | 5.12 | 24K | 434K | SEC |
| 2025-01-28 | 01-29 | Murphy Sean | Chief Manuf, Strategy&Bus Dev. | P 公開市場買進 | 15.0K | 5.17 | 78K | 198K | SEC |
| 2025-01-27 | 01-29 | Young James Emmett | Chief Financial Officer | A 獲配股票 | 12.5K | – | – | 21.7K | SEC |
| 2025-01-27 | 01-29 | Murphy Sean | Chief Manuf, Strategy&Bus Dev. | A 獲配股票 | 12.5K | – | – | 63.3K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| First Light Asset Management, LLC | 6.6M | 29.8M | 新進 | 新進 |
| BlackRock, Inc. | 2.7M | 12.1M | 新進 | 新進 |
| Nantahala Capital Management, LLC | 2.0M | 9.1M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | 7.9M | 新進 | 新進 |
| Cerity Partners LLC | 1.6M | 7.3M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2M | 5.4M | 新進 | 新進 |
| GILDER GAGNON HOWE & CO LLC | 850K | 3.9M | 新進 | 新進 |
| STATE STREET CORP | 611K | 2.8M | 新進 | 新進 |
| WHITE PINE CAPITAL LLC | 548K | 2.5M | 新進 | 新進 |
| KENNEDY CAPITAL MANAGEMENT LLC | 476K | 2.2M | 新進 | 新進 |
| MORGAN STANLEY | 402K | 1.8M | 新進 | 新進 |
| NORTHERN TRUST CORP | 380K | 1.7M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 329K | 1.5M | 新進 | 新進 |
| VANGUARD FIDUCIARY TRUST CO | 321K | 1.5M | 新進 | 新進 |
| Lionhunter Capital Management, LLC | 300K | 1.4M | 新進 | 新進 |
| PERKINS CAPITAL MANAGEMENT INC | 235K | 1.1M | 新進 | 新進 |
| UBS Group AG | 223K | 1.0M | 新進 | 新進 |
| BANK OF AMERICA CORP /DE/ | 205K | 934K | 新進 | 新進 |
| ROYCE & ASSOCIATES LP | 200K | 910K | 新進 | 新進 |
| Corient Private Wealth LP | 147K | 670K | 新進 | 新進 |
| AQR CAPITAL MANAGEMENT LLC | 118K | 537K | 新進 | 新進 |
| Bank of New York Mellon Corp | 112K | 507K | 新進 | 新進 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 108K | 491K | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 82.4K | 375K | 新進 | 新進 |
| CWA Asset Management Group, LLC | 72.0K | 328K | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 79 -5 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 79 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 22.8M · 37.0% |
| 合計季末市值 | 101M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 3.7M |
|---|---|
| 與上期比 | -2.6% |
| 佔流通股數 | 6.00% |
| 日均成交量 | 103K |
| 回補天數 | 35.9 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 3.7M | -2.6% | 6.00% | 103K | 35.9 |
| 2026-08-14 | 3.8M | +0.5% | 6.16% | 271K | 14.0 |
| 2026-07-31 | 3.8M | +5.8% | 6.13% | 170K | 22.2 |
| 2026-07-15 | 3.6M | +15.7% | 5.79% | 277K | 12.9 |
| 2026-06-30 | 3.1M | +40.7% | 5.00% | 679K | 4.5 |
| 2026-06-15 | 2.2M | +4.2% | 3.56% | 324K | 6.8 |
| 2026-05-29 | 2.1M | +24.7% | 3.41% | 428K | 4.9 |
| 2026-05-15 | 1.7M | +16.8% | 2.74% | 1.0M | 1.7 |
| 2026-04-30 | 1.4M | +9.0% | 2.34% | 118K | 12.3 |
| 2026-04-15 | 1.3M | +10.5% | 2.15% | 150K | 8.8 |
| 2026-03-31 | 1.2M | +10.9% | 1.95% | 203K | 5.9 |
| 2026-03-13 | 1.1M | +9.5% | 1.75% | 248K | 4.4 |
| 2026-02-27 | 987K | -15.0% | 1.60% | 239K | 4.1 |
| 2026-02-13 | 1.2M | +2.0% | 1.88% | 102K | 11.4 |
| 2026-01-30 | 1.1M | -9.4% | 1.85% | 137K | 8.3 |
| 2026-01-15 | 1.3M | -2.0% | 2.04% | 136K | 9.2 |
| 2025-12-31 | 1.3M | +61.3% | 2.08% | 242K | 5.3 |
| 2025-12-15 | 795K | +5.3% | 1.29% | 181K | 4.4 |
| 2025-11-28 | 755K | +18.4% | 1.23% | 161K | 4.7 |
| 2025-11-14 | 637K | -0.8% | 1.03% | 105K | 6.1 |
| 2025-10-31 | 643K | -12.0% | 1.04% | 106K | 6.1 |
| 2025-10-15 | 730K | -20.5% | 1.19% | 134K | 5.4 |
| 2025-09-30 | 918K | +78.2% | 1.49% | 158K | 5.8 |
| 2025-09-15 | 515K | +12.8% | 0.84% | 79.3K | 6.5 |
| 2025-08-29 | 457K | -17.3% | 0.74% | 124K | 3.7 |
| 2025-08-15 | 553K | -5.2% | 0.90% | 108K | 5.1 |